James Peyer is the founder and managing partner of Apollo Ventures, an early stage life science investment fund investing in Europe and the U.S. focused exclusively on breakthrough therapeutics arising from the study of the biology of aging. Apollo founds companies with scientists, invests in early stage therapeutics projects, and works with scientific teams to build biotech companies. The company invests in core technologies that show promise in reversing aging and extending human lifespan.
“My whole group thinks of ourselves as scientists first and investors second, and so we really get super, super excited about a specific mechanism of action or a cool new way to develop a drug or a way to target aging,” James says. “That's kind of the hook that brings us into a project much more than some of the traditional financial metrics.”
He also gives talks all over the world on the topic of aging, discussing how our newfound knowledge of what makes us age will enable the greatest medical breakthroughs of the 21st century.
In this episode of Bulletproof Radio, we talk about what venture capital has to do with aging and why it matters that deep investments are being made in the arena of longevity. We touch on bio-freedom, as well as how working intentionally within a system can persuade skeptics and change the world. We cover a lot of ground, including the population effects of longevity, genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, altered intercellular communication, mitochondrial dysfunction and more.
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
